Rifaximin treatment in hepatic encephalopathy

New England Journal of Medicine

Volumn 362, Issue 12, 2010, Pages 1071-1081

  Bass, Nathan M ^a   Mullen, Kevin D ^e   Sanyal, Arun ^g   Poordad, Fred ^c   Neff, Guy ^f   Leevy, Carroll B ^h   Sigal, Samuel ⁱ   Sheikh, Muhammad Y ^a   Beavers, Kimberly ^k   Frederick, Todd ^b   Teperman, Lewis ^j   Hillebrand, Donald ^d   Huang, Shirley ^l   Merchant, Kunal ^l   Shaw, Audrey ^l   Bortey, Enoch ^l   Forbes, William P ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d SCRIPPS CLINIC   (United States)

^e METROHEALTH MEDICAL CENTER   (United States)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^g Virginia Commonwealth Medical Center   (United States)

^h UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Asheville Gastroenterology   (United States)

^l Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; FOLIC ACID; FUROSEMIDE; INSULIN GLARGINE; LACTULOSE; MULTIVITAMIN; NADOLOL; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PLACEBO; PROPRANOLOL; RIFAXIMIN; SPIRONOLACTONE; URSODEOXYCHOLIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; BACTERIAL PERITONITIS; CELLULITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS VARICES; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENERALIZED EDEMA; HAZARD RATIO; HEADACHE; HEMATOCHEZIA; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INCIDENCE; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PATIENT SAFETY; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RISK REDUCTION; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VOMITING;

EID: 77950246404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0907893     Document Type: Article

References (45)

1. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25:Suppl 1:3-9.
2. Munoz SJ. Hepatic encephalopathy. Med Clin North Am 2008;92:795-812.
3. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:95-110.
4. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-741
5. Kalaitzakis E, Josefsson A, Björnsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol 2008;8:46.
6. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-895
7. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007;13: 1366-1371
8. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721
9. Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins, 1979.
10. Córdoba J, Blei AT. Hepatic encephalopathy. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's diseases of the liver. 10th ed. Vol.1. Philadelphia: Lippincott Williams & Wilkins, 2007:569-599
11. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208
12. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology 1977;72:573-583
13. Córdoba J, Mínguez B. Hepatic encephalopathy. Semin Liver Dis 2008;28:70-80.
14. Blei AT, Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976
15. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137: 885-891
16. Morgan MY, Blei A, Grüngreiff K, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007;22:389-405.
17. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046.
18. Bass NM. The current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007;25:Suppl 1: 23-31.
19. Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current medical diagnosis & treatment. 38th ed. Stamford, CT: Appleton & Lange, 1999:1453-1455
20. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009;33:201-205
21. Leitman PS. Liver disease, aminoglycoside antibiotics and renal dysfunction. Hepatology 1988;8:966-968
22. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001;96:2206-2210
23. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-211
24. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 2005;51:Suppl 1: 67-72.
25. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008;20:186-194
26. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118
27. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp 1993;54:598-609.
28. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995;13:274-281
29. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005;46:399-407.
30. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58
31. Loguercio G, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a doubleblind clinical study. Minerva Gastroenterol Dietol 2003;49:53-62.
32. Pedretti G, Calzetti C, Missale G, Fi-accadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178
33. Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23:403-407
34. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial. Curr Med Res Opin 1997;13: 593-601.
35. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064-1070
36. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008;28:1019-1032
37. de Melo RT, Charneski L, Hilas O. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm 2008;65:818-822
38. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009;43:77-84.
39. Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993;4:57-66.
40. Brown RS Jr, Kumar KS, Russo MW, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, post-transplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002;8:278-284
41. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217-231
42. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122-128
43. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555
44. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009-1011
45. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002;14:290-295